Optimizing the Use of BTK Inhibitors in B-Cell Malignancies: Insights for the Multidisciplinary Team—Downloadable Webcast

BTK Inhibitors in B-cell Malignancies Program Image
In this on-demand Webcast, John Allan, MD, reviews available evidence on the use of BTK inhibitors for chronic lymphocytic leukemia, mantle cell lymphoma, and other B-cell malignancies.
Christopher R. Flowers, MD, MS
Program Director
Andrew D. Zelenetz, MD, PhD
Program Director
John Allan, MD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Registered Nurses: 1.0 Nursing contact hour
Pharmacists: 1.0 contact hour (0.1 CEUs)
Released: July 8, 2019 Expiration: July 8, 2020

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Compare and contrast efficacy and adverse event profiles of the available and emerging BTK inhibitors for the treatment of B-cell malignancies
  • Plan optimal therapeutic strategies for patients with MCL, CLL, and WM
  • Explain to patients the importance of and provide strategies for optimal adherence to prescribed oral therapies
  • Apply multidisciplinary treatment decision-making for patients with B-cell malignancies

Information on this Educational Activity

Program Director

Christopher R. Flowers, MD, MS

Director, Lymphoma Program
Medical Director, Oncology Data Center
Associate Professor
Bone Marrow and Stem Cell Transplantation
Department of Hematology and Oncology
Emory University
Atlanta, Georgia

Christopher R. Flowers, MD, MS, has disclosed that he has received consulting fees from AbbVie, Bayer, Denovo Biopharma, Gilead Sciences, Karyopharm, OptumRx, Pharmacyclics/Janssen, and Spectrum and funds for research support from AbbVie, Acerta, Burroughs Wellcome Fund, Celgene, Genentech/Roche, Gilead Sciences, Janssen, Millennium/Takeda, TG Therapeutics, and V Foundation.
Andrew D. Zelenetz, MD, PhD

Medical Director, Quality Informatics
Attending Physician, Lymphoma Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill-Cornell Medical College
New York, New York

Andrew D. Zelenetz, MD, PhD, has disclosed that he has received consulting fees from Adaptive Biotechnologies, Amgen, Celgene, Genentech/Roche, Gilead Sciences, Janssen, and Novartis; funds for research support from Gilead Sciences, MEI Pharma, and Roche; and has received other financial material support from BeiGene.

Faculty

John Allan, MD

Assistant Professor of Medicine
Division of Hematology and Medical Oncology
Weill Cornell Medicine
New York, New York

John Allan, MD, has disclosed that he has served on advisory boards for and received consulting fees from AbbVie, Genentech, Sunesis, Pharmacyclics, and Verastem.

Staff

Terrence Fagan

Associate Scientific Director

Terrence Fagan has no relevant conflicts of interest to report.
Kristen Rosenthal, PhD

Senior Scientific Director

Kristen Rosenthal, PhD, has no relevant conflicts of interest to report.
Taryn O'Loughlin Gross, PhD

Editorial Contributor

Taryn O’Loughlin Gross, PhD, has disclosed that she has received fees for non-CME services from Harmony Biosciences, Saluda Medical, and Shionogi.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Disclosure of Conflicts of Interest

All faculty, staff and reviewers involved in the planning, review or presentation of continuing education activities provided by Purdue University College of Pharmacy are required to disclose to the audience any relevant commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity.

All additional planning committee members, staff and reviewers of Clinical Care Options, LLC and Purdue University College of Pharmacy have no relationships to disclose.

Target Audience

This program is intended for physicians, nurses, pharmacists, and other healthcare providers who care for patients with mantle cell lymphoma, chronic lymphocytic leukemia, or Waldenström’s macroglobulinemia.

Goal

The goal of this activity is to improve participants’ competence in using BTK inhibitors to improve treatment outcomes for patients with mantle cell lymphoma, chronic lymphocytic leukemia, or Waldenström’s macroglobulinemia.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Purdue University College of Pharmacy and Clinical Care Options, LLC. Purdue University College of Pharmacy, an equal access/equal opportunity institution, is accredited by the ACCME to provide continuing medical education for physicians.

Physician Continuing Medical Education

Credit Designation

Purdue University College of Pharmacy designates this enduring material for a maximumof 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation

Purdue University Continuing Nursing Education is accredited  with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

This program has been approved for 1.0 contact hour

Pharmacist Continuing Education

Purdue University College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This is a knowledge based, continuing education activity of Purdue University, an equal access/equal opportunity institution. Universal Activity Number (UAN): 0018-9999-19-045-H01-P, 1.0 contact hours (0.1 CEU).

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from July 08, 2019, through July 08, 2020:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Gain key clinical insights fast with this short slideset from CCO on RET fusion–positive NSCLC

Dara L. Aisner, MD, PhD Joshua Bauml, MD Released: September 17, 2020

Latest evidence on effective management of chronic lymphocytic leukemia (CLL) using BTK inhibitors in this video from Clinical Care Options (CCO)

Danielle Brander, MD Nicole Lamanna, MD Jeff P. Sharman, MD Physicians: maximum of 1.5 AMA PRA Category 1 Credits Released: September 16, 2020 Expired: September 15, 2021

Commentary from Elizabeth R. Plimack, MD, MS on new treatment options, including erdafitinib and enfortumab vedotin, for urothelial cancer from CCO

Elizabeth R. Plimack, MD, MS Released: September 15, 2020

From Clinical Care Options (CCO), expert commentary by Dr Richard Finn on the use of atezolizumab plus bevacizumab for advanced HCC

Richard Finn, MD Released: September 15, 2020
Jointly provided by the Purdue University and Clinical Care Options, LLC
Purdue University Logo

Accreditation: Dawn Sinclair, Purdue University sinclaid@purdue.edu
Certificates/Credits: Heather Holley, Purdue University hholley@purdue.edu

This activity is supported by an educational grant from
AstraZeneca

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?